H. Lundbeck A/S: Depression trials

The registry lists 39 Depression studies with H. Lundbeck A/S as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 1 1Phase 2 9Phase 3 20Phase 4 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Vortioxetine to Prevent Return of Symptoms in Children With DepressionTerminatedNCT05014919Phase 3Results posted
• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeTerminatedNCT02871297Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)CompletedNCT02709746Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)CompletedNCT02709655Phase 3Results posted
• Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive DisorderTerminatedNCT01944969Phase 3Results posted
• Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentCompletedNCT01838681Phase 3Results posted
• Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentTerminatedNCT01837797Phase 3Results posted
• Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian CountriesCompletedNCT01571453Phase 3Results posted
• A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous MedicationCompletedNCT01488071Phase 3Results posted
• Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive DisorderCompletedNCT01422213Phase 3Results posted
• Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT01323478Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT01140906Phase 3Results posted
• Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT00839423Phase 2Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly PatientsCompletedNCT00811252Phase 3Results posted
• Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive DisorderCompletedNCT00807248Phase 2Results posted
• Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00761306Phase 2Results posted
• Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00694304Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive DisorderCompletedNCT00635219Phase 3Results posted
• Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive EpisodesCompletedNCT00596817Phase 3Results posted
• Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From DepressionCompletedNCT04448431Phase 4
• Vortioxetine in Patients With Depression and Early DementiaCompletedNCT04294654Phase 4
• Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in IndiaCompletedNCT04288895Phase 4
• Study With Vortioxetine on Emotional Functioning in Patients With DepressionCompletedNCT03835715Phase 4
• Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With DepressionCompletedNCT03766867Phase 2
• Real-life Effectiveness of Vortioxetine in DepressionCompletedNCT03555136
• Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of AgeCompletedNCT03108625Phase 3
• Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive DisorderCompletedNCT02919501Phase 2
• Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking VortioxetineCompletedNCT02332954Phase 4
• Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive DisorderCompletedNCT02279966Phase 3
• Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive DisorderCompletedNCT02279953Phase 3
• Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive DisorderCompletedNCT02272517Phase 3
• Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in ControlsCompletedNCT01607125Phase 1
• A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive DisorderCompletedNCT01427439
• Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive DisorderCompletedNCT01148472Phase 4
• Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOnCompletedNCT01055379Phase 4
• Efficacy and Safety of Lu AA39959 in Patients With Bipolar DepressionTerminatedNCT00771134Phase 2
• Efficacy and Safety of Lu AA34893 in Patients With Major Depressive DisorderTerminatedNCT00766870Phase 2
• Efficacy and Safety of Lu AA34893 in Patients With Bipolar DepressionTerminatedNCT00622245Phase 2
• Dose-finding Study With Lu AA24530 in Major Depressive DisorderCompletedNCT00599911Phase 2